YBL 013
Alternative Names: ACE-005; ACE-05; Bite-005; BiTE-05; PDL1-ALiCE; YBL-013Latest Information Update: 01 Nov 2023
At a glance
- Originator Y-Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Nov 2023 YBL 013 is still in preclinical trials for Solid tumours in South Korea (Y Biologics pipeline, October 2023)
- 28 Oct 2022 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 06 Jan 2021 YBL 013 licensed to 3D Medicines in Greater China (mainland China, Hong Kong, Macau and Taiwan)